RECOVERY, a large, randomized clinical trial, assessed the efficacy of colchicine, a proposed treatment for inflammation associated with COVID-19.
All articles by Virginia A. Schad, PharmD, RPh
A review of 21 studies evaluated the long-term outcomes associated with pulmonary rehabilitation for patients with pulmonary fibrosis, including ILD.
Researchers sought to evaluate the lifetime risk for ILD in patients with RA and estimate how the MUC5B promoter variant modifies these risks in a real-world setting.
Clinical trial results indicate that ciclesonide inhalation may be an effective early antiviral therapy for mild to moderate COVID-19.
Researchers examining COVID-19 data from a 13-month period found variations in US usage of dexamethasone, remdesivir, and hydroxychloroquine.
Do gastroprotective and promotility agents prevent incident interstitial lung disease in patients with systemic sclerosis?
An NIH review explored whether Bruton tyrosine kinase inhibitors decreased oxygen requirements and hospitalizations for patients with SARS-CoV-2.
Mandatory preprocedurual COVID-19 testing for asymptomatic patients does not necessarily decrease rates of infection among health care workers.
Asthma and chronic obstructive pulmonary disease (COPD) appear to be more common in patients with systemic lupus erythematosus (SLE) than in the general population.
Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.